Fitsum Guebre-Egziabher

Prof. Fitsum Guebre-Egziabher


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Biochimie
Verified
Journal Article
Closed access
Fitsum Guebre-EgziabherFitsum Guebre-Egziabher
Fitsum Guebre-Egziabher
PAPascaline M. Alix
Pascaline M. Alix
Laetitia KOPPELaetitia KOPPE
Laetitia KOPPE
CPCaroline C. Pelletier
Caroline C. Pelletier
EKEmilie Kalbacher
Emilie Kalbacher
CSChristophe O. Soulage
Christophe O. Soulage

1 November 2019 in Toxins
Verified
Journal Article
Open access
PDF file
CPCaroline Pelletier
Caroline Pelletier
MCMikael Croyal
Mikael Croyal
LELavinia Ene
Lavinia Ene
AAAGUESSE Audrey
AGUESSE Audrey
SBStephanie Billon-Crossouard
Stephanie Billon-Crossouard
CSChristophe O. Soulage
Christophe O. Soulage
Gut microbiota-dependent Trimethylamine-N-oxide (TMAO) has been reported to be strongly linked to renal function and to increased cardiovascular events in the general population and in Chronic Kidney Disease (CKD) patients. Considering the lack of data assessing renal handling of TMAO, we conducted this study to explore renal excretion and mechanisms of accumulation of TMAO during CKD. We prospectively measured glomerular filtration rate (mGFR) with gold standard methods and plasma concentrations of trimethylamine (TMA), TMAO, choline, betaine, and carnitine by LC-MS/MS in 124 controls, CKD, and hemodialysis (HD) patients. Renal clearance of each metabolite was assessed in a sub-group of 32 patients. Plasma TMAO was inversely correlated with mGFR (r2 = 0.388, p < 0.001), confirming elevation of TMAO plasma levels in CKD. TMAO clearances were not significantly different from mGFR, with a mean ± SD TMAO fractional excretion of 105% ± 32%. This suggests a complete renal excretion of TMAO by glomerular filtration with a negligible participation of tubular secretion or reabsorption, during all stages of CKD. Moreover, TMAO was effectively removed within 4 h of hemodiafiltration, showing a higher fractional reduction value than that of urea (84.9% ± 6.5% vs. 79.2% ± 5.7%, p = 0.04). This study reports a strong correlation between plasma TMAO levels and mGFR, in CKD, that can be mainly related to a decrease in TMAO glomerular filtration. Clearance data did not support a significant role for tubular secretion in TMAO renal elimination.

25 April 2015 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
SPS. Pelletier
S. Pelletier
CCC. B. Confavreux
C. B. Confavreux
JHJulie Haesebaert
Julie Haesebaert
Fitsum Guebre-EgziabherFitsum Guebre-Egziabher
Fitsum Guebre-Egziabher
JBJustine Bacchetta
Justine Bacchetta
DFDenis Fouque
Denis Fouque

3 September 2020 in Toxins
Verified
Journal Article
Open access
PDF file
CSChristophe O. Soulage
Christophe O. Soulage
CPCaroline Pelletier
Caroline Pelletier
NFNans Florens
Nans Florens
SLSandrine Lemoine
Sandrine Lemoine
LDLaurence Dubourg
Laurence Dubourg
Fitsum Guebre-EgziabherFitsum Guebre-Egziabher
Fitsum Guebre-Egziabher
Lipid aldehydes originating from the peroxidation of n-3 and n-6 polyunsaturated fatty acids are increased in hemodialysis (HD) patients, a process already known to promote oxidative stress. However, data are lacking for patients with chronic kidney disease (CKD) before the initiation of HD. We prospectively evaluated the changes of plasma concentrations of two major lipid aldehydes, 4-HHE and 4-HNE, according to the decrease of glomerular filtration rate (GFR) in 40 CKD and 13 non-CKD participants. GFR was measured by inulin or iohexol clearance. Thus, 4-hydroxy-2-nonenal (4-HNE) and 4-hydroxy-2-hexenal (4-HHE) were quantitated in plasma by gas chromatography coupled with mass spectrometry and their covalent adducts on proteins were quantified by immunoblotting. On the one hand, 4-HHE plasma concentration increased from CKD stage I–II to CKD stage IV–V compared to non-CKD patients (4.5-fold higher in CKD IV–V, p < 0.005). On the other hand, 4-HNE concentration only increased in CKD stage IV–V patients (6.2-fold, p < 0.005). The amount of covalent adducts of 4-HHE on plasma protein was 9.5-fold higher in CKD patients than in controls (p < 0.005), while no difference was observed for 4-HNE protein adducts. Plasma concentrations of 4-HNE and 4-HHE are increased in CKD IV–V patients before the initiation of hemodialysis.

1 May 2013 in Nutrition
Verified
Journal Article
Closed access
Fitsum Guebre-EgziabherFitsum Guebre-Egziabher
Fitsum Guebre-Egziabher
CDCyril Debard
Cyril Debard
JDJocelyne Drai
Jocelyne Drai
LDLaure Denis
Laure Denis
SPSandra Pesenti
Sandra Pesenti
DFDenis Fouque
Denis Fouque

Verified
Journal Article
Open access
PDF file
MSMaxime Schleef
Maxime Schleef
FGFabrice Gonnot
Fabrice Gonnot
BPBruno Pillot
Bruno Pillot
CLChristelle Leon
Christelle Leon
SCStéphanie Chanon
Stéphanie Chanon
SLSandrine Lemoine
Sandrine Lemoine
Renal ischemia-reperfusion (IR) injury can lead to acute kidney injury, increasing the risk of developing chronic kidney disease. We hypothesized that mild therapeutic hypothermia (mTH), 34 °C, applied during ischemia could protect the function and structure of kidneys against IR injuries in mice. In vivo bilateral renal IR led to an increase in plasma urea and acute tubular necrosis at 24 h prevented by mTH. One month after unilateral IR, kidney atrophy and fibrosis were reduced by mTH. Evaluation of mitochondrial function showed that mTH protected against IR-mediated mitochondrial dysfunction at 24 h, by preserving CRC and OX-PHOS. mTH completely abrogated the IR increase of plasmatic IL-6 and IL-10 at 24 h. Acute tissue inflammation was decreased by mTH (IL-6 and IL1-β) in as little as 2 h. Concomitantly, mTH increased TNF-α expression at 24 h. One month after IR, mTH increased TNF-α mRNA expression, and it decreased TGF-β mRNA expression. We showed that mTH alleviates renal dysfunction and damage through a preservation of mitochondrial function and a modulated systemic and local inflammatory response at the acute phase (2–24 h). The protective effect of mTH is maintained in the long term (1 month), as it diminished renal atrophy and fibrosis, and mitigated chronic renal inflammation.